Atea Pharmaceuticals (AVIR) Cash & Equivalents (2020 - 2022)
Historic Cash & Equivalents for Atea Pharmaceuticals (AVIR) over the last 3 years, with Q3 2022 value amounting to $176.4 million.
- Atea Pharmaceuticals' Cash & Equivalents fell 7899.03% to $176.4 million in Q3 2022 from the same period last year, while for Sep 2022 it was $176.4 million, marking a year-over-year decrease of 7899.03%. This contributed to the annual value of $764.4 million for FY2021, which is 1008.59% down from last year.
- Per Atea Pharmaceuticals' latest filing, its Cash & Equivalents stood at $176.4 million for Q3 2022, which was down 7899.03% from $684.5 million recorded in Q2 2022.
- Atea Pharmaceuticals' 5-year Cash & Equivalents high stood at $850.1 million for Q4 2020, and its period low was $17.1 million during Q1 2020.
- In the last 3 years, Atea Pharmaceuticals' Cash & Equivalents had a median value of $705.5 million in 2022 and averaged $537.2 million.
- Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 476237.24% in 2021, then plummeted by 7899.03% in 2022.
- Quarter analysis of 3 years shows Atea Pharmaceuticals' Cash & Equivalents stood at $850.1 million in 2020, then dropped by 10.09% to $764.4 million in 2021, then tumbled by 76.92% to $176.4 million in 2022.
- Its Cash & Equivalents stands at $176.4 million for Q3 2022, versus $684.5 million for Q2 2022 and $705.5 million for Q1 2022.